Harvard Bioscience Announces Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $22.2 million, up 8% year over year
- ➤Q3 net loss widened to $(2.6) million from $(1.2) million
- ➤Q3 gross margin fell to 55.4% from 58.4%
- ➤Full-year 2026 revenue growth guidance reaffirmed at 3%-5%
- ➤Full-year adjusted EBITDA target updated to (1%) to 4% growth
Expert Statements
John Duke, President and Chief Executive Officer of Harvard Bioscience
“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products. Our revamped sales and marketing teams are delivering encouraging results, and Project Viking remains on track for completion by the end of the first quarter in 2027. Looking ahead, our sales momentum, continued New Product Innovation (NPI) adoption, and progress on key initiatives give us confidence in the trajectory of the business.”
* Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million * Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the third quarter ended September 30, 2026.
“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter,” said John Duke, President and Chief Executive Officer. “We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products. Our revamped sales and marketing teams are delivering encouraging results, and Project Viking remains on track for completion by the end of the first quarter in 2027. Looking ahead, our sales momentum, continued New Product Innovation (NPI) adoption, and progress on key initiatives give us confidence in the trajectory of the business.”
Get started
Create a free account to read the full story.